-
2
-
-
27944433469
-
Oncolytic viral therapies - the clinical experience
-
doi:10.1038/sj.onc.1209037
-
Aghi M, Martuza RL. Oncolytic viral therapies - the clinical experience. Oncogene (2005) 24:7802-16. doi:10.1038/sj.onc.1209037
-
(2005)
Oncogene
, vol.24
, pp. 7802-7816
-
-
Aghi, M.1
Martuza, R.L.2
-
3
-
-
0030917202
-
ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents
-
doi:10.1038/nm0697-639
-
Heise C, Sampson-Johannes A, Williams A, McCormick F, Von Hoff DD, Kirn DH. ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nat Med (1997) 3:639-45. doi:10.1038/nm0697-639
-
(1997)
Nat Med
, vol.3
, pp. 639-645
-
-
Heise, C.1
Sampson-Johannes, A.2
Williams, A.3
McCormick, F.4
Von Hoff, D.D.5
Kirn, D.H.6
-
4
-
-
33644852717
-
China approves world's first oncolytic virus therapy for cancer treatment
-
doi:10.1093/jnci/djj111
-
Garber K. China approves world's first oncolytic virus therapy for cancer treatment. J Natl Cancer Inst (2006) 98:298-300. doi:10.1093/jnci/djj111
-
(2006)
J Natl Cancer Inst
, vol.98
, pp. 298-300
-
-
Garber, K.1
-
5
-
-
80053000452
-
Strategies to enhance viral penetration of solid tumors
-
doi:10.1089/hum.2010.227
-
Smith E, Breznik J, Lichty BD. Strategies to enhance viral penetration of solid tumors. Hum Gene Ther (2011) 22:1053-60. doi:10.1089/hum.2010.227
-
(2011)
Hum Gene Ther
, vol.22
, pp. 1053-1060
-
-
Smith, E.1
Breznik, J.2
Lichty, B.D.3
-
6
-
-
70450200778
-
The case of oncolytic viruses versus the immune system: waiting on the judgment of Solomon
-
doi:10.1089/hum.2009.135
-
Prestwich RJ, Errington F, Diaz RM, Pandha HS, Harrington KJ, Melcher AA, et al. The case of oncolytic viruses versus the immune system: waiting on the judgment of Solomon. Hum Gene Ther (2009) 20:1119-32. doi:10.1089/hum.2009.135
-
(2009)
Hum Gene Ther
, vol.20
, pp. 1119-1132
-
-
Prestwich, R.J.1
Errington, F.2
Diaz, R.M.3
Pandha, H.S.4
Harrington, K.J.5
Melcher, A.A.6
-
7
-
-
77953172635
-
Type III IFN interleukin-28 mediates the antitumor efficacy of oncolytic virus VSV in immune-competent mouse models of cancer
-
doi:10.1158/0008-5472.CAN-09-4658
-
Wongthida P, Diaz RM, Galivo F, Kottke T, Thompson J, Pulido J, et al. Type III IFN interleukin-28 mediates the antitumor efficacy of oncolytic virus VSV in immune-competent mouse models of cancer. Cancer Res (2010) 70:4539-49. doi:10.1158/0008-5472.CAN-09-4658
-
(2010)
Cancer Res
, vol.70
, pp. 4539-4549
-
-
Wongthida, P.1
Diaz, R.M.2
Galivo, F.3
Kottke, T.4
Thompson, J.5
Pulido, J.6
-
8
-
-
84874309252
-
Oncolytic vaccinia virus disrupts tumor-associated vasculature in humans
-
doi:10.1158/0008-5472.CAN-12-2687
-
Breitbach CJ, Arulanandam R, De SN, Thorne SH, Patt R, Daneshmand M, et al. Oncolytic vaccinia virus disrupts tumor-associated vasculature in humans. Cancer Res (2013) 73:1265-75. doi:10.1158/0008-5472.CAN-12-2687
-
(2013)
Cancer Res
, vol.73
, pp. 1265-1275
-
-
Breitbach, C.J.1
Arulanandam, R.2
De, S.N.3
Thorne, S.H.4
Patt, R.5
Daneshmand, M.6
-
9
-
-
34548062828
-
Targeted inflammation during oncolytic virus therapy severely compromises tumor blood flow
-
doi:10.1038/sj.mt.6300215
-
Breitbach CJ, Paterson JM, Lemay CG, Falls TJ, McGuire A, Parato KA, et al. Targeted inflammation during oncolytic virus therapy severely compromises tumor blood flow. Mol Ther (2007) 15:1686-93. doi:10.1038/sj.mt.6300215
-
(2007)
Mol Ther
, vol.15
, pp. 1686-1693
-
-
Breitbach, C.J.1
Paterson, J.M.2
Lemay, C.G.3
Falls, T.J.4
McGuire, A.5
Parato, K.A.6
-
10
-
-
79551614963
-
Adaptive antiviral immunity is a determinant of the therapeutic success of oncolytic virotherapy
-
doi:10.1038/mt.2010.264
-
Sobol PT, Boudreau JE, Stephenson K, Wan Y, Lichty BD, Mossman KL. Adaptive antiviral immunity is a determinant of the therapeutic success of oncolytic virotherapy. Mol Ther (2011) 19:335-44. doi:10.1038/mt.2010.264
-
(2011)
Mol Ther
, vol.19
, pp. 335-344
-
-
Sobol, P.T.1
Boudreau, J.E.2
Stephenson, K.3
Wan, Y.4
Lichty, B.D.5
Mossman, K.L.6
-
11
-
-
1542514777
-
Myeloid differentiation factor 88 is required for cross-priming in vivo
-
doi:10.4049/jimmunol.172.6.3415
-
Palliser D, Ploegh H, Boes M. Myeloid differentiation factor 88 is required for cross-priming in vivo. J Immunol (2004) 172:3415-21. doi:10.4049/jimmunol.172.6.3415
-
(2004)
J Immunol
, vol.172
, pp. 3415-3421
-
-
Palliser, D.1
Ploegh, H.2
Boes, M.3
-
12
-
-
20044382430
-
Toll-like receptor 3 promotes cross-priming to virus-infected cells
-
doi:10.1038/nature03326
-
Schulz O, Diebold SS, Chen M, Naslund TI, Nolte MA, Alexopoulou L, et al. Toll-like receptor 3 promotes cross-priming to virus-infected cells. Nature (2005) 433:887-92. doi:10.1038/nature03326
-
(2005)
Nature
, vol.433
, pp. 887-892
-
-
Schulz, O.1
Diebold, S.S.2
Chen, M.3
Naslund, T.I.4
Nolte, M.A.5
Alexopoulou, L.6
-
13
-
-
44249100151
-
Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial
-
doi:10.1016/S1470-2045(08)70107-4
-
Park BH, Hwang T, Liu TC, Sze DY, Kim JS, Kwon HC, et al. Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial. Lancet Oncol (2008) 9:533-42. doi:10.1016/S1470-2045(08)70107-4
-
(2008)
Lancet Oncol
, vol.9
, pp. 533-542
-
-
Park, B.H.1
Hwang, T.2
Liu, T.C.3
Sze, D.Y.4
Kim, J.S.5
Kwon, H.C.6
-
14
-
-
77957253429
-
OPTIM trial: a Phase III trial of an oncolytic herpes virus encoding GM-CSF for unresectable stage III or IV melanoma
-
doi:10.2217/fon.10.66
-
Kaufman HL, Bines SD. OPTIM trial: a Phase III trial of an oncolytic herpes virus encoding GM-CSF for unresectable stage III or IV melanoma. Future Oncol (2010) 6:941-9. doi:10.2217/fon.10.66
-
(2010)
Future Oncol
, vol.6
, pp. 941-949
-
-
Kaufman, H.L.1
Bines, S.D.2
-
15
-
-
54749109597
-
Immunosuppression enhances oncolytic adenovirus replication and antitumor efficacy in the Syrian hamster model
-
doi:10.1038/mt.2008.162
-
Thomas MA, Spencer JF, Toth K, Sagartz JE, Phillips NJ, Wold WS. Immunosuppression enhances oncolytic adenovirus replication and antitumor efficacy in the Syrian hamster model. Mol Ther (2008) 16:1665-73. doi:10.1038/mt.2008.162
-
(2008)
Mol Ther
, vol.16
, pp. 1665-1673
-
-
Thomas, M.A.1
Spencer, J.F.2
Toth, K.3
Sagartz, J.E.4
Phillips, N.J.5
Wold, W.S.6
-
16
-
-
84883642231
-
Oncolytic viruses as therapeutic cancer vaccines.
-
doi:10.1186/1476-4598-12-103
-
Bartlett DL, Liu Z, Sathaiah M, Ravindranathan R, Guo Z, He Y, et al. Oncolytic viruses as therapeutic cancer vaccines. Mol Cancer (2013) 12:103. doi:10.1186/1476-4598-12-103
-
(2013)
Mol Cancer
, vol.12
, pp. 103
-
-
Bartlett, D.L.1
Liu, Z.2
Sathaiah, M.3
Ravindranathan, R.4
Guo, Z.5
He, Y.6
-
17
-
-
65349092744
-
Viral subversion of immunogenic cell death
-
doi:10.4161/cc.8.6.7939
-
Kepp O, Senovilla L, Galluzzi L, Panaretakis T, Tesniere A, Schlemmer F, et al. Viral subversion of immunogenic cell death. Cell Cycle (2009) 8:860-9. doi:10.4161/cc.8.6.7939
-
(2009)
Cell Cycle
, vol.8
, pp. 860-869
-
-
Kepp, O.1
Senovilla, L.2
Galluzzi, L.3
Panaretakis, T.4
Tesniere, A.5
Schlemmer, F.6
-
19
-
-
57649149333
-
Classification of cell death: recommendations of the Nomenclature Committee on Cell Death 2009
-
doi:10.1038/cdd.2008.150
-
Kroemer G, Galluzzi L, Vandenabeele P, Abrams J, Alnemri ES, Baehrecke EH, et al. Classification of cell death: recommendations of the Nomenclature Committee on Cell Death 2009. Cell Death Differ (2009) 16:3-11. doi:10.1038/cdd.2008.150
-
(2009)
Cell Death Differ
, vol.16
, pp. 3-11
-
-
Kroemer, G.1
Galluzzi, L.2
Vandenabeele, P.3
Abrams, J.4
Alnemri, E.S.5
Baehrecke, E.H.6
-
20
-
-
0032519925
-
Macrophages that have ingested apoptotic cells in vitro inhibit proinflammatory cytokine production through autocrine/paracrine mechanisms involving TGF-beta, PGE2, and PAF
-
doi:10.1172/JCI1112
-
Fadok VA, Bratton DL, Konowal A, Freed PW, Westcott JY, Henson PM. Macrophages that have ingested apoptotic cells in vitro inhibit proinflammatory cytokine production through autocrine/paracrine mechanisms involving TGF-beta, PGE2, and PAF. J Clin Invest (1998) 101:890-8. doi:10.1172/JCI1112
-
(1998)
J Clin Invest
, vol.101
, pp. 890-898
-
-
Fadok, V.A.1
Bratton, D.L.2
Konowal, A.3
Freed, P.W.4
Westcott, J.Y.5
Henson, P.M.6
-
21
-
-
0035338504
-
Differential effects of apoptotic versus lysed cells on macrophage production of cytokines: role of proteases
-
doi:10.4049/jimmunol.166.11.6847
-
Fadok VA, Bratton DL, Guthrie L, Henson PM. Differential effects of apoptotic versus lysed cells on macrophage production of cytokines: role of proteases. J Immunol (2001) 166:6847-54. doi:10.4049/jimmunol.166.11.6847
-
(2001)
J Immunol
, vol.166
, pp. 6847-6854
-
-
Fadok, V.A.1
Bratton, D.L.2
Guthrie, L.3
Henson, P.M.4
-
22
-
-
75749147533
-
Immunogenic death of colon cancer cells treated with oxaliplatin
-
doi:10.1038/onc.2009.356
-
Tesniere A, Schlemmer F, Boige V, Kepp O, Martins I, Ghiringhelli F, et al. Immunogenic death of colon cancer cells treated with oxaliplatin. Oncogene (2010) 29:482-91. doi:10.1038/onc.2009.356
-
(2010)
Oncogene
, vol.29
, pp. 482-491
-
-
Tesniere, A.1
Schlemmer, F.2
Boige, V.3
Kepp, O.4
Martins, I.5
Ghiringhelli, F.6
-
23
-
-
29144530630
-
Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death
-
doi:10.1084/jem.20050915
-
Casares N, Pequignot MO, Tesniere A, Ghiringhelli F, Roux S, Chaput N, et al. Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. J Exp Med (2005) 202:1691-701. doi:10.1084/jem.20050915
-
(2005)
J Exp Med
, vol.202
, pp. 1691-1701
-
-
Casares, N.1
Pequignot, M.O.2
Tesniere, A.3
Ghiringhelli, F.4
Roux, S.5
Chaput, N.6
-
24
-
-
84875552922
-
Immunogenic cell death in cancer therapy
-
doi:10.1146/annurev-immunol-032712-100008
-
Kroemer G, Galluzzi L, Kepp O, Zitvogel L. Immunogenic cell death in cancer therapy. Annu Rev Immunol (2013) 31:51-72. doi:10.1146/annurev-immunol-032712-100008
-
(2013)
Annu Rev Immunol
, vol.31
, pp. 51-72
-
-
Kroemer, G.1
Galluzzi, L.2
Kepp, O.3
Zitvogel, L.4
-
25
-
-
7644238045
-
Conditionally replicating adenoviruses kill tumor cells via a basic apoptotic machinery-independent mechanism that resembles necrosis-like programmed cell death
-
doi:10.1128/JVI.78.22.12243-12251.2004
-
Abou E, Hassan MA, van Meulen-Muileman I, Abbas S, Kruyt FA. Conditionally replicating adenoviruses kill tumor cells via a basic apoptotic machinery-independent mechanism that resembles necrosis-like programmed cell death. J Virol (2004) 78:12243-51. doi:10.1128/JVI.78.22.12243-12251.2004
-
(2004)
J Virol
, vol.78
, pp. 12243-12251
-
-
Abou, E.1
Hassan, M.A.2
van Meulen-Muileman, I.3
Abbas, S.4
Kruyt, F.A.5
-
26
-
-
84887431193
-
Vaccinia virus induces programmed necrosis in ovarian cancer cells
-
doi:10.1038/mt.2013.195
-
Whilding LM, Archibald KM, Kulbe H, Balkwill FR, Oberg D, McNeish IA. Vaccinia virus induces programmed necrosis in ovarian cancer cells. Mol Ther (2013) 21:2074-86. doi:10.1038/mt.2013.195
-
(2013)
Mol Ther
, vol.21
, pp. 2074-2086
-
-
Whilding, L.M.1
Archibald, K.M.2
Kulbe, H.3
Balkwill, F.R.4
Oberg, D.5
McNeish, I.A.6
-
28
-
-
79952810024
-
Catalytic activity of the caspase-8-FLIP(L) complex inhibits RIPK3-dependent necrosis
-
doi:10.1038/nature09852
-
Oberst A, Dillon CP, Weinlich R, McCormick LL, Fitzgerald P, Pop C, et al. Catalytic activity of the caspase-8-FLIP(L) complex inhibits RIPK3-dependent necrosis. Nature (2011) 471:363-7. doi:10.1038/nature09852
-
(2011)
Nature
, vol.471
, pp. 363-367
-
-
Oberst, A.1
Dillon, C.P.2
Weinlich, R.3
McCormick, L.L.4
Fitzgerald, P.5
Pop, C.6
-
29
-
-
84891343566
-
Plasma membrane translocation of trimerized MLKL protein is required for TNF-induced necroptosis
-
doi:10.1038/ncb2883
-
Cai Z, Jitkaew S, Zhao J, Chiang HC, Choksi S, Liu J, et al. Plasma membrane translocation of trimerized MLKL protein is required for TNF-induced necroptosis. Nat Cell Biol (2014) 16:55-65. doi:10.1038/ncb2883
-
(2014)
Nat Cell Biol
, vol.16
, pp. 55-65
-
-
Cai, Z.1
Jitkaew, S.2
Zhao, J.3
Chiang, H.C.4
Choksi, S.5
Liu, J.6
-
30
-
-
84896541259
-
True grit: programmed necrosis in antiviral host defense, inflammation, and immunogenicity
-
doi:10.4049/jimmunol.1302426
-
Mocarski ES, Kaiser WJ, Livingston-Rosanoff D, Upton JW, Daley-Bauer LP. True grit: programmed necrosis in antiviral host defense, inflammation, and immunogenicity. J Immunol (2014) 192:2019-26. doi:10.4049/jimmunol.1302426
-
(2014)
J Immunol
, vol.192
, pp. 2019-2026
-
-
Mocarski, E.S.1
Kaiser, W.J.2
Livingston-Rosanoff, D.3
Upton, J.W.4
Daley-Bauer, L.P.5
-
31
-
-
79952811804
-
RIP3 mediates the embryonic lethality of caspase-8-deficient mice
-
doi:10.1038/nature09857
-
Kaiser WJ, Upton JW, Long AB, Livingston-Rosanoff D, Daley-Bauer LP, Hakem R, et al. RIP3 mediates the embryonic lethality of caspase-8-deficient mice. Nature (2011) 471:368-72. doi:10.1038/nature09857
-
(2011)
Nature
, vol.471
, pp. 368-372
-
-
Kaiser, W.J.1
Upton, J.W.2
Long, A.B.3
Livingston-Rosanoff, D.4
Daley-Bauer, L.P.5
Hakem, R.6
-
32
-
-
66449133280
-
Phosphorylation-driven assembly of the RIP1-RIP3 complex regulates programmed necrosis and virus-induced inflammation
-
doi:10.1016/j.cell.2009.05.037
-
Cho YS, Challa S, Moquin D, Genga R, Ray TD, Guildford M, et al. Phosphorylation-driven assembly of the RIP1-RIP3 complex regulates programmed necrosis and virus-induced inflammation. Cell (2009) 137:1112-23. doi:10.1016/j.cell.2009.05.037
-
(2009)
Cell
, vol.137
, pp. 1112-1123
-
-
Cho, Y.S.1
Challa, S.2
Moquin, D.3
Genga, R.4
Ray, T.D.5
Guildford, M.6
-
33
-
-
77954593965
-
Virus inhibition of RIP3-dependent necrosis
-
doi:10.1016/j.chom.2010.03.006
-
Upton JW, Kaiser WJ, Mocarski ES. Virus inhibition of RIP3-dependent necrosis. Cell Host Microbe (2010) 7:302-13. doi:10.1016/j.chom.2010.03.006
-
(2010)
Cell Host Microbe
, vol.7
, pp. 302-313
-
-
Upton, J.W.1
Kaiser, W.J.2
Mocarski, E.S.3
-
34
-
-
84874559930
-
Akt Regulates TNFalpha synthesis downstream of RIP1 kinase activation during necroptosis.
-
doi:10.1371/journal.pone.0056576
-
McNamara CR, Ahuja R, Osafo-Addo AD, Barrows D, Kettenbach A, Skidan I, et al. Akt Regulates TNFalpha synthesis downstream of RIP1 kinase activation during necroptosis. PLoS One (2013) 8:e56576. doi:10.1371/journal.pone.0056576
-
(2013)
PLoS One
, vol.8
-
-
McNamara, C.R.1
Ahuja, R.2
Osafo-Addo, A.D.3
Barrows, D.4
Kettenbach, A.5
Skidan, I.6
-
35
-
-
77957191110
-
Antitumoural immunity by virus-mediated immunogenic apoptosis inhibits metastatic growth of hepatocellular carcinoma
-
doi:10.1136/gut.2009.196519
-
Boozari B, Mundt B, Woller N, Struver N, Gurlevik E, Schache P, et al. Antitumoural immunity by virus-mediated immunogenic apoptosis inhibits metastatic growth of hepatocellular carcinoma. Gut (2010) 59:1416-26. doi:10.1136/gut.2009.196519
-
(2010)
Gut
, vol.59
, pp. 1416-1426
-
-
Boozari, B.1
Mundt, B.2
Woller, N.3
Struver, N.4
Gurlevik, E.5
Schache, P.6
-
36
-
-
84877580504
-
IL-24 sensitizes tumor cells to TLR3-mediated apoptosis
-
doi:10.1038/cdd.2013.15
-
Weiss R, Sachet M, Zinngrebe J, Aschacher T, Krainer M, Hegedus B, et al. IL-24 sensitizes tumor cells to TLR3-mediated apoptosis. Cell Death Differ (2013) 20:823-33. doi:10.1038/cdd.2013.15
-
(2013)
Cell Death Differ
, vol.20
, pp. 823-833
-
-
Weiss, R.1
Sachet, M.2
Zinngrebe, J.3
Aschacher, T.4
Krainer, M.5
Hegedus, B.6
-
37
-
-
67349269904
-
Autophagy enhances the presentation of endogenous viral antigens on MHC class I molecules during HSV-1 infection
-
doi:10.1038/ni.1720
-
English L, Chemali M, Duron J, Rondeau C, Laplante A, Gingras D, et al. Autophagy enhances the presentation of endogenous viral antigens on MHC class I molecules during HSV-1 infection. Nat Immunol (2009) 10:480-7. doi:10.1038/ni.1720
-
(2009)
Nat Immunol
, vol.10
, pp. 480-487
-
-
English, L.1
Chemali, M.2
Duron, J.3
Rondeau, C.4
Laplante, A.5
Gingras, D.6
-
38
-
-
33646462468
-
Autophagic cell death of malignant glioma cells induced by a conditionally replicating adenovirus
-
doi:10.1093/jnci/djj161
-
Ito H, Aoki H, Kuhnel F, Kondo Y, Kubicka S, Wirth T, et al. Autophagic cell death of malignant glioma cells induced by a conditionally replicating adenovirus. J Natl Cancer Inst (2006) 98:625-36. doi:10.1093/jnci/djj161
-
(2006)
J Natl Cancer Inst
, vol.98
, pp. 625-636
-
-
Ito, H.1
Aoki, H.2
Kuhnel, F.3
Kondo, Y.4
Kubicka, S.5
Wirth, T.6
-
39
-
-
34748880650
-
Examination of the therapeutic potential of Delta-24-RGD in brain tumor stem cells: role of autophagic cell death
-
doi:10.1093/jnci/djm102
-
Jiang H, Gomez-Manzano C, Aoki H, Alonso MM, Kondo S, McCormick F, et al. Examination of the therapeutic potential of Delta-24-RGD in brain tumor stem cells: role of autophagic cell death. J Natl Cancer Inst (2007) 99:1410-4. doi:10.1093/jnci/djm102
-
(2007)
J Natl Cancer Inst
, vol.99
, pp. 1410-1414
-
-
Jiang, H.1
Gomez-Manzano, C.2
Aoki, H.3
Alonso, M.M.4
Kondo, S.5
McCormick, F.6
-
40
-
-
84862813177
-
Newcastle disease virus triggers autophagy in U251 glioma cells to enhance virus replication
-
doi:10.1007/s00705-012-1270-6
-
Meng C, Zhou Z, Jiang K, Yu S, Jia L, Wu Y, et al. Newcastle disease virus triggers autophagy in U251 glioma cells to enhance virus replication. Arch Virol (2012) 157:1011-8. doi:10.1007/s00705-012-1270-6
-
(2012)
Arch Virol
, vol.157
, pp. 1011-1018
-
-
Meng, C.1
Zhou, Z.2
Jiang, K.3
Yu, S.4
Jia, L.5
Wu, Y.6
-
41
-
-
84890871141
-
Autophagy benefits the replication of Newcastle disease virus in chicken cells and tissues
-
doi:10.1128/JVI.01849-13
-
Sun Y, Yu S, Ding N, Meng C, Meng S, Zhang S, et al. Autophagy benefits the replication of Newcastle disease virus in chicken cells and tissues. J Virol (2014) 88:525-37. doi:10.1128/JVI.01849-13
-
(2014)
J Virol
, vol.88
, pp. 525-537
-
-
Sun, Y.1
Yu, S.2
Ding, N.3
Meng, C.4
Meng, S.5
Zhang, S.6
-
42
-
-
50049112424
-
Autophagy-inducing agents augment the antitumor effect of telerase-selve oncolytic adenovirus OBP-405 on glioblastoma cells
-
doi:10.1038/gt.2008.98
-
Yokoyama T, Iwado E, Kondo Y, Aoki H, Hayashi Y, Georgescu MM, et al. Autophagy-inducing agents augment the antitumor effect of telerase-selve oncolytic adenovirus OBP-405 on glioblastoma cells. Gene Ther (2008) 15:1233-9. doi:10.1038/gt.2008.98
-
(2008)
Gene Ther
, vol.15
, pp. 1233-1239
-
-
Yokoyama, T.1
Iwado, E.2
Kondo, Y.3
Aoki, H.4
Hayashi, Y.5
Georgescu, M.M.6
-
43
-
-
84897487697
-
Mitophagy enhances oncolytic measles virus replication by mitigating DDX58/RIG-I-like receptor signaling
-
doi:10.1128/JVI.03851-13
-
Xia M, Gonzalez P, Li C, Meng G, Jiang A, Wang H, et al. Mitophagy enhances oncolytic measles virus replication by mitigating DDX58/RIG-I-like receptor signaling. J Virol (2014) 88:5152-64. doi:10.1128/JVI.03851-13
-
(2014)
J Virol
, vol.88
, pp. 5152-5164
-
-
Xia, M.1
Gonzalez, P.2
Li, C.3
Meng, G.4
Jiang, A.5
Wang, H.6
-
44
-
-
84865299726
-
PAMPs and DAMPs: signal 0s that spur autophagy and immunity
-
doi:10.1111/j.1600-065X.2012.01146.x
-
Tang D, Kang R, Coyne CB, Zeh HJ, Lotze MT. PAMPs and DAMPs: signal 0s that spur autophagy and immunity. Immunol Rev (2012) 249:158-75. doi:10.1111/j.1600-065X.2012.01146.x
-
(2012)
Immunol Rev
, vol.249
, pp. 158-175
-
-
Tang, D.1
Kang, R.2
Coyne, C.B.3
Zeh, H.J.4
Lotze, M.T.5
-
45
-
-
0028201732
-
Tolerance, danger, and the extended family
-
doi:10.1146/annurev.immunol.12.1.991
-
Matzinger P. Tolerance, danger, and the extended family. Annu Rev Immunol (1994) 12:991-1045. doi:10.1146/annurev.immunol.12.1.991
-
(1994)
Annu Rev Immunol
, vol.12
, pp. 991-1045
-
-
Matzinger, P.1
-
46
-
-
70249090374
-
Nucleotides released by apoptotic cells act as a find-me signal to promote phagocytic clearance
-
doi:10.1038/nature08296
-
Elliott MR, Chekeni FB, Trampont PC, Lazarowski ER, Kadl A, Walk SF, et al. Nucleotides released by apoptotic cells act as a find-me signal to promote phagocytic clearance. Nature (2009) 461:282-6. doi:10.1038/nature08296
-
(2009)
Nature
, vol.461
, pp. 282-286
-
-
Elliott, M.R.1
Chekeni, F.B.2
Trampont, P.C.3
Lazarowski, E.R.4
Kadl, A.5
Walk, S.F.6
-
47
-
-
77957942834
-
Pannexin 1 channels mediate 'find-me' signal release and membrane permeability during apoptosis
-
doi:10.1038/nature09413
-
Chekeni FB, Elliott MR, Sandilos JK, Walk SF, Kinchen JM, Lazarowski ER, et al. Pannexin 1 channels mediate 'find-me' signal release and membrane permeability during apoptosis. Nature (2010) 467:863-7. doi:10.1038/nature09413
-
(2010)
Nature
, vol.467
, pp. 863-867
-
-
Chekeni, F.B.1
Elliott, M.R.2
Sandilos, J.K.3
Walk, S.F.4
Kinchen, J.M.5
Lazarowski, E.R.6
-
48
-
-
70350569295
-
Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors
-
doi:10.1038/nm.2028
-
Ghiringhelli F, Apetoh L, Tesniere A, Aymeric L, Ma Y, Ortiz C, et al. Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors. Nat Med (2009) 15:1170-8. doi:10.1038/nm.2028
-
(2009)
Nat Med
, vol.15
, pp. 1170-1178
-
-
Ghiringhelli, F.1
Apetoh, L.2
Tesniere, A.3
Aymeric, L.4
Ma, Y.5
Ortiz, C.6
-
49
-
-
84878530852
-
Oncolytic adenovirus with temozolomide induces autophagy and antitumor immune responses in cancer patients
-
doi:10.1038/mt.2013.51
-
Liikanen I, Ahtiainen L, Hirvinen ML, Bramante S, Cerullo V, Nokisalmi P, et al. Oncolytic adenovirus with temozolomide induces autophagy and antitumor immune responses in cancer patients. Mol Ther (2013) 21:1212-23. doi:10.1038/mt.2013.51
-
(2013)
Mol Ther
, vol.21
, pp. 1212-1223
-
-
Liikanen, I.1
Ahtiainen, L.2
Hirvinen, M.L.3
Bramante, S.4
Cerullo, V.5
Nokisalmi, P.6
-
50
-
-
84861112821
-
Coxsackievirus B3 is an oncolytic virus with immunostimulatory properties that is active against lung adenocarcinoma
-
doi:10.1158/0008-5472.CAN-11-3185
-
Miyamoto S, Inoue H, Nakamura T, Yamada M, Sakamoto C, Urata Y, et al. Coxsackievirus B3 is an oncolytic virus with immunostimulatory properties that is active against lung adenocarcinoma. Cancer Res (2012) 72:2609-21. doi:10.1158/0008-5472.CAN-11-3185
-
(2012)
Cancer Res
, vol.72
, pp. 2609-2621
-
-
Miyamoto, S.1
Inoue, H.2
Nakamura, T.3
Yamada, M.4
Sakamoto, C.5
Urata, Y.6
-
51
-
-
84857997683
-
A novel pathway combining calreticulin exposure and ATP secretion in immunogenic cancer cell death
-
doi:10.1038/emboj.2011.497
-
Garg AD, Krysko DV, Verfaillie T, Kaczmarek A, Ferreira GB, Marysael T, et al. A novel pathway combining calreticulin exposure and ATP secretion in immunogenic cancer cell death. EMBO J (2012) 31:1062-79. doi:10.1038/emboj.2011.497
-
(2012)
EMBO J
, vol.31
, pp. 1062-1079
-
-
Garg, A.D.1
Krysko, D.V.2
Verfaillie, T.3
Kaczmarek, A.4
Ferreira, G.B.5
Marysael, T.6
-
52
-
-
35748933181
-
Ecto-calreticulin in immunogenic chemotherapy
-
doi:10.1111/j.1600-065X.2007.00567.x
-
Obeid M, Tesniere A, Panaretakis T, Tufi R, Joza N, van Endert P, et al. Ecto-calreticulin in immunogenic chemotherapy. Immunol Rev (2007) 220:22-34. doi:10.1111/j.1600-065X.2007.00567.x
-
(2007)
Immunol Rev
, vol.220
, pp. 22-34
-
-
Obeid, M.1
Tesniere, A.2
Panaretakis, T.3
Tufi, R.4
Joza, N.5
van Endert, P.6
-
53
-
-
84860520650
-
Immune response is an important aspect of the antitumor effect produced by a CD40L-encoding oncolytic adenovirus
-
doi:10.1158/0008-5472.CAN-11-2975
-
Diaconu I, Cerullo V, Hirvinen ML, Escutenaire S, Ugolini M, Pesonen SK, et al. Immune response is an important aspect of the antitumor effect produced by a CD40L-encoding oncolytic adenovirus. Cancer Res (2012) 72:2327-38. doi:10.1158/0008-5472.CAN-11-2975
-
(2012)
Cancer Res
, vol.72
, pp. 2327-2338
-
-
Diaconu, I.1
Cerullo, V.2
Hirvinen, M.L.3
Escutenaire, S.4
Ugolini, M.5
Pesonen, S.K.6
-
54
-
-
0037062934
-
Release of chromatin protein HMGB1 by necrotic cells triggers inflammation
-
doi:10.1038/nature00858
-
Scaffidi P, Misteli T, Bianchi ME. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature (2002) 418:191-5. doi:10.1038/nature00858
-
(2002)
Nature
, vol.418
, pp. 191-195
-
-
Scaffidi, P.1
Misteli, T.2
Bianchi, M.E.3
-
55
-
-
84883747524
-
Crosstalk between ER stress and immunogenic cell death
-
doi:10.1016/j.cytogfr.2013.05.001
-
Kepp O, Menger L, Vacchelli E, Locher C, Adjemian S, Yamazaki T, et al. Crosstalk between ER stress and immunogenic cell death. Cytokine Growth Factor Rev (2013) 24:311-8. doi:10.1016/j.cytogfr.2013.05.001
-
(2013)
Cytokine Growth Factor Rev
, vol.24
, pp. 311-318
-
-
Kepp, O.1
Menger, L.2
Vacchelli, E.3
Locher, C.4
Adjemian, S.5
Yamazaki, T.6
-
56
-
-
84871985834
-
Measles virus causes immunogenic cell death in human melanoma
-
doi:10.1038/gt.2011.205
-
Donnelly OG, Errington-Mais F, Steele L, Hadac E, Jennings V, Scott K, et al. Measles virus causes immunogenic cell death in human melanoma. Gene Ther (2013) 20:7-15. doi:10.1038/gt.2011.205
-
(2013)
Gene Ther
, vol.20
, pp. 7-15
-
-
Donnelly, O.G.1
Errington-Mais, F.2
Steele, L.3
Hadac, E.4
Jennings, V.5
Scott, K.6
-
57
-
-
27544491235
-
The enhanced tumor selectivity of an oncolytic vaccinia lacking the host range and antiapoptosis genes SPI-1 and SPI-2
-
doi:10.1158/0008-5472.CAN-05-1630
-
Guo ZS, Naik A, O'Malley ME, Popovic P, Demarco R, Hu Y, et al. The enhanced tumor selectivity of an oncolytic vaccinia lacking the host range and antiapoptosis genes SPI-1 and SPI-2. Cancer Res (2005) 65:9991-8. doi:10.1158/0008-5472.CAN-05-1630
-
(2005)
Cancer Res
, vol.65
, pp. 9991-9998
-
-
Guo, Z.S.1
Naik, A.2
O'Malley, M.E.3
Popovic, P.4
Demarco, R.5
Hu, Y.6
-
58
-
-
0038277131
-
Oncolytic parvovirus H1 induces release of heat-shock protein HSP72 in susceptible human tumor cells but may not affect primary immune cells
-
doi:10.1038/sj.cgt.7700591
-
Moehler M, Zeidler M, Schede J, Rommelaere J, Galle PR, Cornelis JJ, et al. Oncolytic parvovirus H1 induces release of heat-shock protein HSP72 in susceptible human tumor cells but may not affect primary immune cells. Cancer Gene Ther (2003) 10:477-80. doi:10.1038/sj.cgt.7700591
-
(2003)
Cancer Gene Ther
, vol.10
, pp. 477-480
-
-
Moehler, M.1
Zeidler, M.2
Schede, J.3
Rommelaere, J.4
Galle, P.R.5
Cornelis, J.J.6
-
59
-
-
77953187290
-
Uric acid promotes an acute inflammatory response to sterile cell death in mice
-
doi:10.1172/JCI40124
-
Kono H, Chen CJ, Ontiveros F, Rock KL. Uric acid promotes an acute inflammatory response to sterile cell death in mice. J Clin Invest (2010) 120:1939-49. doi:10.1172/JCI40124
-
(2010)
J Clin Invest
, vol.120
, pp. 1939-1949
-
-
Kono, H.1
Chen, C.J.2
Ontiveros, F.3
Rock, K.L.4
-
60
-
-
42049104455
-
Virus-mediated oncolysis induces danger signal and stimulates cytotoxic T-lymphocyte activity via proteasome activator upregulation
-
doi:10.1038/sj.onc.1210884
-
Endo Y, Sakai R, Ouchi M, Onimatsu H, Hioki M, Kagawa S, et al. Virus-mediated oncolysis induces danger signal and stimulates cytotoxic T-lymphocyte activity via proteasome activator upregulation. Oncogene (2008) 27:2375-81. doi:10.1038/sj.onc.1210884
-
(2008)
Oncogene
, vol.27
, pp. 2375-2381
-
-
Endo, Y.1
Sakai, R.2
Ouchi, M.3
Onimatsu, H.4
Hioki, M.5
Kagawa, S.6
-
61
-
-
84887416895
-
Peptidases released by necrotic cells control CD8+ T cell cross-priming
-
doi:10.1172/JCI65698
-
Gamrekelashvili J, Kapanadze T, Han M, Wissing J, Ma C, Jaensch L, et al. Peptidases released by necrotic cells control CD8+ T cell cross-priming. J Clin Invest (2013) 123:4755-68. doi:10.1172/JCI65698
-
(2013)
J Clin Invest
, vol.123
, pp. 4755-4768
-
-
Gamrekelashvili, J.1
Kapanadze, T.2
Han, M.3
Wissing, J.4
Ma, C.5
Jaensch, L.6
-
62
-
-
80054764086
-
Virus-tumor interactome screen reveals ER stress response can reprogram resistant cancers for oncolytic virus-triggered caspase-2 cell death
-
doi:10.1016/j.ccr.2011.09.005
-
Mahoney DJ, Lefebvre C, Allan K, Brun J, Sanaei CA, Baird S, et al. Virus-tumor interactome screen reveals ER stress response can reprogram resistant cancers for oncolytic virus-triggered caspase-2 cell death. Cancer Cell (2011) 20:443-56. doi:10.1016/j.ccr.2011.09.005
-
(2011)
Cancer Cell
, vol.20
, pp. 443-456
-
-
Mahoney, D.J.1
Lefebvre, C.2
Allan, K.3
Brun, J.4
Sanaei, C.A.5
Baird, S.6
-
63
-
-
84862705997
-
Reovirus therapy stimulates endoplasmic reticular stress, NOXA induction, and augments bortezomib-mediated apoptosis in multiple myeloma
-
doi:10.1038/onc.2011.478
-
Kelly KR, Espitia CM, Mahalingam D, Oyajobi BO, Coffey M, Giles FJ, et al. Reovirus therapy stimulates endoplasmic reticular stress, NOXA induction, and augments bortezomib-mediated apoptosis in multiple myeloma. Oncogene (2012) 31:3023-38. doi:10.1038/onc.2011.478
-
(2012)
Oncogene
, vol.31
, pp. 3023-3038
-
-
Kelly, K.R.1
Espitia, C.M.2
Mahalingam, D.3
Oyajobi, B.O.4
Coffey, M.5
Giles, F.J.6
-
64
-
-
84904390050
-
Bortezomib-induced unfolded protein response increases oncolytic HSV-1 replication resulting in synergistic, anti-tumor effects.
-
doi:10.1158/1078-0432.CCR-14-0553
-
Yoo JY, Hurwitz BS, Bolyard C, Yu JG, Zhang J, Selvendiran K, et al. Bortezomib-induced unfolded protein response increases oncolytic HSV-1 replication resulting in synergistic, anti-tumor effects. Clin Cancer Res (2014). doi:10.1158/1078-0432.CCR-14-0553
-
(2014)
Clin Cancer Res
-
-
Yoo, J.Y.1
Hurwitz, B.S.2
Bolyard, C.3
Yu, J.G.4
Zhang, J.5
Selvendiran, K.6
-
65
-
-
58149359320
-
Tumor infection by oncolytic reovirus primes adaptive antitumor immunity
-
doi:10.1158/1078-0432.CCR-08-0831
-
Prestwich RJ, Errington F, Ilett EJ, Morgan RS, Scott KJ, Kottke T, et al. Tumor infection by oncolytic reovirus primes adaptive antitumor immunity. Clin Cancer Res (2008) 14:7358-66. doi:10.1158/1078-0432.CCR-08-0831
-
(2008)
Clin Cancer Res
, vol.14
, pp. 7358-7366
-
-
Prestwich, R.J.1
Errington, F.2
Ilett, E.J.3
Morgan, R.S.4
Scott, K.J.5
Kottke, T.6
-
66
-
-
33645066093
-
Degradation of fibrillar collagen in a human melanoma xenograft improves the efficacy of an oncolytic herpes simplex virus vector
-
doi:10.1158/0008-5472.CAN-05-2242
-
McKee TD, Grandi P, Mok W, Alexandrakis G, Insin N, Zimmer JP, et al. Degradation of fibrillar collagen in a human melanoma xenograft improves the efficacy of an oncolytic herpes simplex virus vector. Cancer Res (2006) 66:2509-13. doi:10.1158/0008-5472.CAN-05-2242
-
(2006)
Cancer Res
, vol.66
, pp. 2509-2513
-
-
McKee, T.D.1
Grandi, P.2
Mok, W.3
Alexandrakis, G.4
Insin, N.5
Zimmer, J.P.6
-
67
-
-
36348930079
-
Matrix metalloproteinases-1 and -8 improve the distribution and efficacy of an oncolytic virus
-
doi:10.1158/0008-5472.CAN-07-3107
-
Mok W, Boucher Y, Jain RK. Matrix metalloproteinases-1 and -8 improve the distribution and efficacy of an oncolytic virus. Cancer Res (2007) 67:10664-8. doi:10.1158/0008-5472.CAN-07-3107
-
(2007)
Cancer Res
, vol.67
, pp. 10664-10668
-
-
Mok, W.1
Boucher, Y.2
Jain, R.K.3
-
68
-
-
68249158537
-
Virus binding to a plasma membrane receptor triggers interleukin-1 alpha-mediated proinflammatory macrophage response in vivo
-
doi:10.1016/j.immuni.2009.04.015
-
Di Paolo NC, Miao EA, Iwakura Y, Murali-Krishna K, Aderem A, Flavell RA, et al. Virus binding to a plasma membrane receptor triggers interleukin-1 alpha-mediated proinflammatory macrophage response in vivo. Immunity (2009) 31:110-21. doi:10.1016/j.immuni.2009.04.015
-
(2009)
Immunity
, vol.31
, pp. 110-121
-
-
Di Paolo, N.C.1
Miao, E.A.2
Iwakura, Y.3
Murali-Krishna, K.4
Aderem, A.5
Flavell, R.A.6
-
69
-
-
84879796258
-
The transcription factor IRF3 triggers "defensive suicide" necrosis in response to viral and bacterial pathogens
-
doi:10.1016/j.celrep.2013.05.025
-
Di Paolo NC, Doronin K, Baldwin LK, Papayannopoulou T, Shayakhmetov DM. The transcription factor IRF3 triggers "defensive suicide" necrosis in response to viral and bacterial pathogens. Cell Rep (2013) 3:1840-6. doi:10.1016/j.celrep.2013.05.025
-
(2013)
Cell Rep
, vol.3
, pp. 1840-1846
-
-
Di Paolo, N.C.1
Doronin, K.2
Baldwin, L.K.3
Papayannopoulou, T.4
Shayakhmetov, D.M.5
-
70
-
-
0141953995
-
Neutrophils contribute to the measles virus-induced antitumor effect: enhancement by granulocyte macrophage colony-stimulating factor expression.
-
Grote D, Cattaneo R, Fielding AK. Neutrophils contribute to the measles virus-induced antitumor effect: enhancement by granulocyte macrophage colony-stimulating factor expression. Cancer Res (2003) 63:6463-8.
-
(2003)
Cancer Res
, vol.63
, pp. 6463-6468
-
-
Grote, D.1
Cattaneo, R.2
Fielding, A.K.3
-
71
-
-
84861874828
-
Expression of immunomodulatory neutrophil-activating protein of Helicobacter pylori enhances the antitumor activity of oncolytic measles virus
-
doi:10.1038/mt.2012.4
-
Iankov ID, Allen C, Federspiel MJ, Myers RM, Peng KW, Ingle JN, et al. Expression of immunomodulatory neutrophil-activating protein of Helicobacter pylori enhances the antitumor activity of oncolytic measles virus. Mol Ther (2012) 20:1139-47. doi:10.1038/mt.2012.4
-
(2012)
Mol Ther
, vol.20
, pp. 1139-1147
-
-
Iankov, I.D.1
Allen, C.2
Federspiel, M.J.3
Myers, R.M.4
Peng, K.W.5
Ingle, J.N.6
-
72
-
-
84863017298
-
Attenuated, oncolytic, but not wild-type measles virus infection has pleiotropic effects on human neutrophil function
-
doi:10.4049/jimmunol.1102262
-
Zhang Y, Patel B, Dey A, Ghorani E, Rai L, Elham M, et al. Attenuated, oncolytic, but not wild-type measles virus infection has pleiotropic effects on human neutrophil function. J Immunol (2012) 188:1002-10. doi:10.4049/jimmunol.1102262
-
(2012)
J Immunol
, vol.188
, pp. 1002-1010
-
-
Zhang, Y.1
Patel, B.2
Dey, A.3
Ghorani, E.4
Rai, L.5
Elham, M.6
-
73
-
-
0032814773
-
Oncolytic virus therapy of multiple tumors in the brain requires suppression of innate and elicited antiviral responses
-
doi:10.1038/11320
-
Ikeda K, Ichikawa T, Wakimoto H, Silver JS, Deisboeck TS, Finkelstein D, et al. Oncolytic virus therapy of multiple tumors in the brain requires suppression of innate and elicited antiviral responses. Nat Med (1999) 5:881-7. doi:10.1038/11320
-
(1999)
Nat Med
, vol.5
, pp. 881-887
-
-
Ikeda, K.1
Ichikawa, T.2
Wakimoto, H.3
Silver, J.S.4
Deisboeck, T.S.5
Finkelstein, D.6
-
74
-
-
37549027165
-
Exponential enhancement of oncolytic vesicular stomatitis virus potency by vector-mediated suppression of inflammatory responses in vivo
-
doi:10.1038/sj.mt.6300343
-
Altomonte J, Wu L, Chen L, Meseck M, Ebert O, Garcia-Sastre A, et al. Exponential enhancement of oncolytic vesicular stomatitis virus potency by vector-mediated suppression of inflammatory responses in vivo. Mol Ther (2008) 16:146-53. doi:10.1038/sj.mt.6300343
-
(2008)
Mol Ther
, vol.16
, pp. 146-153
-
-
Altomonte, J.1
Wu, L.2
Chen, L.3
Meseck, M.4
Ebert, O.5
Garcia-Sastre, A.6
-
75
-
-
84870909657
-
NK cells impede glioblastoma virotherapy through NKp30 and NKp46 natural cytotoxicity receptors
-
doi:10.1038/nm.3013
-
Alvarez-Breckenridge CA, Yu J, Price R, Wojton J, Pradarelli J, Mao H, et al. NK cells impede glioblastoma virotherapy through NKp30 and NKp46 natural cytotoxicity receptors. Nat Med (2012) 18:1827-34. doi:10.1038/nm.3013
-
(2012)
Nat Med
, vol.18
, pp. 1827-1834
-
-
Alvarez-Breckenridge, C.A.1
Yu, J.2
Price, R.3
Wojton, J.4
Pradarelli, J.5
Mao, H.6
-
76
-
-
33748088164
-
Cyclophosphamide enhances glioma virotherapy by inhibiting innate immune responses
-
doi:10.1073/pnas.0605496103
-
Fulci G, Breymann L, Gianni D, Kurozomi K, Rhee SS, Yu J, et al. Cyclophosphamide enhances glioma virotherapy by inhibiting innate immune responses. Proc Natl Acad Sci U S A (2006) 103:12873-8. doi:10.1073/pnas.0605496103
-
(2006)
Proc Natl Acad Sci U S A
, vol.103
, pp. 12873-12878
-
-
Fulci, G.1
Breymann, L.2
Gianni, D.3
Kurozomi, K.4
Rhee, S.S.5
Yu, J.6
-
77
-
-
84876303245
-
Innate immune defense defines susceptibility of sarcoma cells to measles vaccine virus-based oncolysis
-
doi:10.1128/JVI.02106-12
-
Berchtold S, Lampe J, Weiland T, Smirnow I, Schleicher S, Handgretinger R, et al. Innate immune defense defines susceptibility of sarcoma cells to measles vaccine virus-based oncolysis. J Virol (2013) 87:3484-501. doi:10.1128/JVI.02106-12
-
(2013)
J Virol
, vol.87
, pp. 3484-3501
-
-
Berchtold, S.1
Lampe, J.2
Weiland, T.3
Smirnow, I.4
Schleicher, S.5
Handgretinger, R.6
-
78
-
-
84880757177
-
Deciphering and reversing tumor immune suppression
-
doi:10.1016/j.immuni.2013.07.005
-
Motz GT, Coukos G. Deciphering and reversing tumor immune suppression. Immunity (2013) 39:61-73. doi:10.1016/j.immuni.2013.07.005
-
(2013)
Immunity
, vol.39
, pp. 61-73
-
-
Motz, G.T.1
Coukos, G.2
-
79
-
-
77956976681
-
Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm
-
doi:10.1038/ni.1937
-
Biswas SK, Mantovani A. Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat Immunol (2010) 11:889-96. doi:10.1038/ni.1937
-
(2010)
Nat Immunol
, vol.11
, pp. 889-896
-
-
Biswas, S.K.1
Mantovani, A.2
-
80
-
-
84857883847
-
Macrophage plasticity and polarization: in vivo veritas
-
doi:10.1172/JCI59643
-
Sica A, Mantovani A. Macrophage plasticity and polarization: in vivo veritas. J Clin Invest (2012) 122:787-95. doi:10.1172/JCI59643
-
(2012)
J Clin Invest
, vol.122
, pp. 787-795
-
-
Sica, A.1
Mantovani, A.2
-
81
-
-
35148871720
-
Depletion of peripheral macrophages and brain microglia increases brain tumor titers of oncolytic viruses
-
doi:10.1158/0008-5472.CAN-07-1063
-
Fulci G, Dmitrieva N, Gianni D, Fontana EJ, Pan X, Lu Y, et al. Depletion of peripheral macrophages and brain microglia increases brain tumor titers of oncolytic viruses. Cancer Res (2007) 67:9398-406. doi:10.1158/0008-5472.CAN-07-1063
-
(2007)
Cancer Res
, vol.67
, pp. 9398-9406
-
-
Fulci, G.1
Dmitrieva, N.2
Gianni, D.3
Fontana, E.J.4
Pan, X.5
Lu, Y.6
-
82
-
-
69249222379
-
Polarization of tumor-associated neutrophil phenotype by TGF-beta: "N1" versus "N2" TAN
-
doi:10.1016/j.ccr.2009.06.017
-
Fridlender ZG, Sun J, Kim S, Kapoor V, Cheng G, Ling L, et al. Polarization of tumor-associated neutrophil phenotype by TGF-beta: "N1" versus "N2" TAN. Cancer Cell (2009) 16:183-94. doi:10.1016/j.ccr.2009.06.017
-
(2009)
Cancer Cell
, vol.16
, pp. 183-194
-
-
Fridlender, Z.G.1
Sun, J.2
Kim, S.3
Kapoor, V.4
Cheng, G.5
Ling, L.6
-
83
-
-
54849440346
-
Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy
-
doi:10.1007/s00262-008-0523-4
-
Diaz-Montero CM, Salem ML, Nishimura MI, Garrett-Mayer E, Cole DJ, Montero AJ. Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy. Cancer Immunol Immunother (2009) 58:49-59. doi:10.1007/s00262-008-0523-4
-
(2009)
Cancer Immunol Immunother
, vol.58
, pp. 49-59
-
-
Diaz-Montero, C.M.1
Salem, M.L.2
Nishimura, M.I.3
Garrett-Mayer, E.4
Cole, D.J.5
Montero, A.J.6
-
84
-
-
84872132293
-
Activated tumor-infiltrating CD4+ regulatory T cells restrain antitumor immunity in patients with primary or metastatic liver cancer
-
doi:10.1002/hep.26013
-
Pedroza-Gonzalez A, Verhoef C, Ijzermans JN, Peppelenbosch MP, Kwekkeboom J, Verheij J, et al. Activated tumor-infiltrating CD4+ regulatory T cells restrain antitumor immunity in patients with primary or metastatic liver cancer. Hepatology (2013) 57:183-94. doi:10.1002/hep.26013
-
(2013)
Hepatology
, vol.57
, pp. 183-194
-
-
Pedroza-Gonzalez, A.1
Verhoef, C.2
Ijzermans, J.N.3
Peppelenbosch, M.P.4
Kwekkeboom, J.5
Verheij, J.6
-
85
-
-
16844379997
-
Immunosuppressive networks in the tumour environment and their therapeutic relevance
-
doi:10.1038/nrc1586
-
Zou W. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer (2005) 5:263-74. doi:10.1038/nrc1586
-
(2005)
Nat Rev Cancer
, vol.5
, pp. 263-274
-
-
Zou, W.1
-
86
-
-
25144466458
-
Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity
-
doi:10.1158/1078-0432.CCR-05-0883
-
Suzuki E, Kapoor V, Jassar AS, Kaiser LR, Albelda SM. Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity. Clin Cancer Res (2005) 11:6713-21. doi:10.1158/1078-0432.CCR-05-0883
-
(2005)
Clin Cancer Res
, vol.11
, pp. 6713-6721
-
-
Suzuki, E.1
Kapoor, V.2
Jassar, A.S.3
Kaiser, L.R.4
Albelda, S.M.5
-
87
-
-
84873097527
-
Enhanced antitumoral activity of oncolytic herpes simplex virus with gemcitabine using colorectal tumor models
-
doi:10.1002/ijc.27823
-
Esaki S, Goshima F, Kimura H, Murakami S, Nishiyama Y. Enhanced antitumoral activity of oncolytic herpes simplex virus with gemcitabine using colorectal tumor models. Int J Cancer (2013) 132:1592-601. doi:10.1002/ijc.27823
-
(2013)
Int J Cancer
, vol.132
, pp. 1592-1601
-
-
Esaki, S.1
Goshima, F.2
Kimura, H.3
Murakami, S.4
Nishiyama, Y.5
-
88
-
-
0030902366
-
The prognostic significance of intratumoral natural killer cells in patients with colorectal carcinoma
-
doi:10.1002/(SICI)1097-0142(19970615)79:12<3C2320::AID-CNCR5>3E3.0.CO;2-P
-
Coca S, Perez-Piqueras J, Martinez D, Colmenarejo A, Saez MA, Vallejo C, et al. The prognostic significance of intratumoral natural killer cells in patients with colorectal carcinoma. Cancer (1997) 79:2320-8. doi:10.1002/(SICI)1097-0142(19970615)79:12<3C2320::AID-CNCR5>3E3.0.CO;2-P
-
(1997)
Cancer
, vol.79
, pp. 2320-2328
-
-
Coca, S.1
Perez-Piqueras, J.2
Martinez, D.3
Colmenarejo, A.4
Saez, M.A.5
Vallejo, C.6
-
89
-
-
0033009888
-
Natural killer cells in antiviral defense: function and regulation by innate cytokines
-
doi:10.1146/annurev.immunol.17.1.189
-
Biron CA, Nguyen KB, Pien GC, Cousens LP, Salazar-Mather TP. Natural killer cells in antiviral defense: function and regulation by innate cytokines. Annu Rev Immunol (1999) 17:189-220. doi:10.1146/annurev.immunol.17.1.189
-
(1999)
Annu Rev Immunol
, vol.17
, pp. 189-220
-
-
Biron, C.A.1
Nguyen, K.B.2
Pien, G.C.3
Cousens, L.P.4
Salazar-Mather, T.P.5
-
90
-
-
60149101705
-
Enhanced oncolytic potency of vesicular stomatitis virus through vector-mediated inhibition of NK and NKT cells
-
doi:10.1038/cgt.2008.74
-
Altomonte J, Wu L, Meseck M, Chen L, Ebert O, Garcia-Sastre A, et al. Enhanced oncolytic potency of vesicular stomatitis virus through vector-mediated inhibition of NK and NKT cells. Cancer Gene Ther (2009) 16:266-78. doi:10.1038/cgt.2008.74
-
(2009)
Cancer Gene Ther
, vol.16
, pp. 266-278
-
-
Altomonte, J.1
Wu, L.2
Meseck, M.3
Chen, L.4
Ebert, O.5
Garcia-Sastre, A.6
-
91
-
-
34047262198
-
Oncolytic immunovirotherapy for melanoma using vesicular stomatitis virus
-
doi:10.1158/0008-5472.CAN-06-3974
-
Diaz RM, Galivo F, Kottke T, Wongthida P, Qiao J, Thompson J, et al. Oncolytic immunovirotherapy for melanoma using vesicular stomatitis virus. Cancer Res (2007) 67:2840-8. doi:10.1158/0008-5472.CAN-06-3974
-
(2007)
Cancer Res
, vol.67
, pp. 2840-2848
-
-
Diaz, R.M.1
Galivo, F.2
Kottke, T.3
Wongthida, P.4
Qiao, J.5
Thompson, J.6
-
92
-
-
79953294511
-
Oncolytic virus-initiated protective immunity against prostate cancer
-
doi:10.1038/mt.2010.297
-
Gujar SA, Pan DA, Marcato P, Garant KA, Lee PW. Oncolytic virus-initiated protective immunity against prostate cancer. Mol Ther (2011) 19:797-804. doi:10.1038/mt.2010.297
-
(2011)
Mol Ther
, vol.19
, pp. 797-804
-
-
Gujar, S.A.1
Pan, D.A.2
Marcato, P.3
Garant, K.A.4
Lee, P.W.5
-
93
-
-
84861871116
-
ORFV: a novel oncolytic and immune stimulating parapoxvirus therapeutic
-
doi:10.1038/mt.2011.301
-
Rintoul JL, Lemay CG, Tai LH, Stanford MM, Falls TJ, de Souza CT, et al. ORFV: a novel oncolytic and immune stimulating parapoxvirus therapeutic. Mol Ther (2012) 20:1148-57. doi:10.1038/mt.2011.301
-
(2012)
Mol Ther
, vol.20
, pp. 1148-1157
-
-
Rintoul, J.L.1
Lemay, C.G.2
Tai, L.H.3
Stanford, M.M.4
Falls, T.J.5
de Souza, C.T.6
-
94
-
-
84871959360
-
Preventing postoperative metastatic disease by inhibiting surgery-induced dysfunction in natural killer cells
-
doi:10.1158/0008-5472.CAN-12-1993
-
Tai LH, de Souza CT, Belanger S, Ly L, Alkayyal AA, Zhang J, et al. Preventing postoperative metastatic disease by inhibiting surgery-induced dysfunction in natural killer cells. Cancer Res (2013) 73:97-107. doi:10.1158/0008-5472.CAN-12-1993
-
(2013)
Cancer Res
, vol.73
, pp. 97-107
-
-
Tai, L.H.1
de Souza, C.T.2
Belanger, S.3
Ly, L.4
Alkayyal, A.A.5
Zhang, J.6
-
95
-
-
84884576997
-
Perioperative influenza vaccination reduces postoperative metastatic disease by reversing surgery-induced dysfunction in natural killer cells
-
doi:10.1158/1078-0432.CCR-13-0246
-
Tai LH, Zhang J, Scott KJ, de Souza CT, Alkayyal AA, Ananth AA, et al. Perioperative influenza vaccination reduces postoperative metastatic disease by reversing surgery-induced dysfunction in natural killer cells. Clin Cancer Res (2013) 19:5104-15. doi:10.1158/1078-0432.CCR-13-0246
-
(2013)
Clin Cancer Res
, vol.19
, pp. 5104-5115
-
-
Tai, L.H.1
Zhang, J.2
Scott, K.J.3
de Souza, C.T.4
Alkayyal, A.A.5
Ananth, A.A.6
-
96
-
-
34548020722
-
Coadministration of a herpes simplex virus-2 based oncolytic virus and cyclophosphamide produces a synergistic antitumor effect and enhances tumor-specific immune responses
-
doi:10.1158/0008-5472.CAN-07-1087
-
Li H, Zeng Z, Fu X, Zhang X. Coadministration of a herpes simplex virus-2 based oncolytic virus and cyclophosphamide produces a synergistic antitumor effect and enhances tumor-specific immune responses. Cancer Res (2007) 67:7850-5. doi:10.1158/0008-5472.CAN-07-1087
-
(2007)
Cancer Res
, vol.67
, pp. 7850-7855
-
-
Li, H.1
Zeng, Z.2
Fu, X.3
Zhang, X.4
-
97
-
-
36148993947
-
Preclinical pharmacology and toxicology of intravenous MV-NIS, an oncolytic measles virus administered with or without cyclophosphamide
-
doi:10.1038/sj.clpt.6100409
-
Myers RM, Greiner SM, Harvey ME, Griesmann G, Kuffel MJ, Buhrow SA, et al. Preclinical pharmacology and toxicology of intravenous MV-NIS, an oncolytic measles virus administered with or without cyclophosphamide. Clin Pharmacol Ther (2007) 82:700-10. doi:10.1038/sj.clpt.6100409
-
(2007)
Clin Pharmacol Ther
, vol.82
, pp. 700-710
-
-
Myers, R.M.1
Greiner, S.M.2
Harvey, M.E.3
Griesmann, G.4
Kuffel, M.J.5
Buhrow, S.A.6
-
98
-
-
84903789456
-
Maraba MG1 virus enhances natural killer cell function via conventional dendritic cells to reduce postoperative metastatic disease
-
doi:10.1038/mt.2014.60
-
Zhang J, Tai LH, Ilkow CS, Alkayyal AA, Ananth AA, de Souza CT, et al. Maraba MG1 virus enhances natural killer cell function via conventional dendritic cells to reduce postoperative metastatic disease. Mol Ther (2014) 22:1320-32. doi:10.1038/mt.2014.60
-
(2014)
Mol Ther
, vol.22
, pp. 1320-1332
-
-
Zhang, J.1
Tai, L.H.2
Ilkow, C.S.3
Alkayyal, A.A.4
Ananth, A.A.5
de Souza, C.T.6
-
99
-
-
84877096819
-
Cetuximab-activated natural killer and dendritic cells collaborate to trigger tumor antigen-specific T-cell immunity in head and neck cancer patients
-
doi:10.1158/1078-0432.CCR-12-2426
-
Srivastava RM, Lee SC, Andrade Filho PA, Lord CA, Jie HB, Davidson HC, et al. Cetuximab-activated natural killer and dendritic cells collaborate to trigger tumor antigen-specific T-cell immunity in head and neck cancer patients. Clin Cancer Res (2013) 19:1858-72. doi:10.1158/1078-0432.CCR-12-2426
-
(2013)
Clin Cancer Res
, vol.19
, pp. 1858-1872
-
-
Srivastava, R.M.1
Lee, S.C.2
Andrade Filho, P.A.3
Lord, C.A.4
Jie, H.B.5
Davidson, H.C.6
-
100
-
-
84878279239
-
Oncolytic and immunotherapeutic vaccinia induces antibody-mediated complement-dependent cancer cell lysis in humans.
-
185ra63, doi:10.1126/scitranslmed.3005361
-
Kim MK, Breitbach CJ, Moon A, Heo J, Lee YK, Cho M, et al. Oncolytic and immunotherapeutic vaccinia induces antibody-mediated complement-dependent cancer cell lysis in humans. Sci Transl Med (2013) 5:185ra63. doi:10.1126/scitranslmed.3005361
-
(2013)
Sci Transl Med
, vol.5
-
-
Kim, M.K.1
Breitbach, C.J.2
Moon, A.3
Heo, J.4
Lee, Y.K.5
Cho, M.6
-
101
-
-
34447277894
-
Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection
-
doi:10.1200/JCO.2006.09.4565
-
Gao Q, Qiu SJ, Fan J, Zhou J, Wang XY, Xiao YS, et al. Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection. J Clin Oncol (2007) 25:2586-93. doi:10.1200/JCO.2006.09.4565
-
(2007)
J Clin Oncol
, vol.25
, pp. 2586-2593
-
-
Gao, Q.1
Qiu, S.J.2
Fan, J.3
Zhou, J.4
Wang, X.Y.5
Xiao, Y.S.6
-
102
-
-
84884287627
-
Treg and CTLA-4: two intertwining pathways to immune tolerance
-
doi:10.1016/j.jaut.2013.06.006
-
Walker LS. Treg and CTLA-4: two intertwining pathways to immune tolerance. J Autoimmun (2013) 45:49-57. doi:10.1016/j.jaut.2013.06.006
-
(2013)
J Autoimmun
, vol.45
, pp. 49-57
-
-
Walker, L.S.1
-
103
-
-
70449377991
-
Tregs control the development of symptomatic West Nile virus infection in humans and mice
-
doi:10.1172/JCI39387
-
Lanteri MC, O'Brien KM, Purtha WE, Cameron MJ, Lund JM, Owen RE, et al. Tregs control the development of symptomatic West Nile virus infection in humans and mice. J Clin Invest (2009) 119:3266-77. doi:10.1172/JCI39387
-
(2009)
J Clin Invest
, vol.119
, pp. 3266-3277
-
-
Lanteri, M.C.1
O'Brien, K.M.2
Purtha, W.E.3
Cameron, M.J.4
Lund, J.M.5
Owen, R.E.6
-
104
-
-
70449532980
-
Decrease of Foxp3+ Treg cell number and acquisition of effector cell phenotype during lethal infection
-
doi:10.1016/j.immuni.2009.10.001
-
Oldenhove G, Bouladoux N, Wohlfert EA, Hall JA, Chou D, Dos SL, et al. Decrease of Foxp3+ Treg cell number and acquisition of effector cell phenotype during lethal infection. Immunity (2009) 31:772-86. doi:10.1016/j.immuni.2009.10.001
-
(2009)
Immunity
, vol.31
, pp. 772-786
-
-
Oldenhove, G.1
Bouladoux, N.2
Wohlfert, E.A.3
Hall, J.A.4
Chou, D.5
Dos, S.L.6
-
105
-
-
45749096230
-
Treg depletion-enhanced IL-2 treatment facilitates therapy of established tumors using systemically delivered oncolytic virus
-
doi:10.1038/mt.2008.83
-
Kottke T, Galivo F, Wongthida P, Diaz RM, Thompson J, Jevremovic D, et al. Treg depletion-enhanced IL-2 treatment facilitates therapy of established tumors using systemically delivered oncolytic virus. Mol Ther (2008) 16:1217-26. doi:10.1038/mt.2008.83
-
(2008)
Mol Ther
, vol.16
, pp. 1217-1226
-
-
Kottke, T.1
Galivo, F.2
Wongthida, P.3
Diaz, R.M.4
Thompson, J.5
Jevremovic, D.6
-
106
-
-
59449108246
-
Improved systemic delivery of oncolytic reovirus to established tumors using preconditioning with cyclophosphamide-mediated Treg modulation and interleukin-2
-
doi:10.1158/1078-0432.CCR-08-1688
-
Kottke T, Thompson J, Diaz RM, Pulido J, Willmon C, Coffey M, et al. Improved systemic delivery of oncolytic reovirus to established tumors using preconditioning with cyclophosphamide-mediated Treg modulation and interleukin-2. Clin Cancer Res (2009) 15:561-9. doi:10.1158/1078-0432.CCR-08-1688
-
(2009)
Clin Cancer Res
, vol.15
, pp. 561-569
-
-
Kottke, T.1
Thompson, J.2
Diaz, R.M.3
Pulido, J.4
Willmon, C.5
Coffey, M.6
-
107
-
-
84880376084
-
Multifaceted oncolytic virus therapy for glioblastoma in an immunocompetent cancer stem cell model
-
doi:10.1073/pnas.1307935110
-
Cheema TA, Wakimoto H, Fecci PE, Ning J, Kuroda T, Jeyaretna DS, et al. Multifaceted oncolytic virus therapy for glioblastoma in an immunocompetent cancer stem cell model. Proc Natl Acad Sci U S A (2013) 110:12006-11. doi:10.1073/pnas.1307935110
-
(2013)
Proc Natl Acad Sci U S A
, vol.110
, pp. 12006-12011
-
-
Cheema, T.A.1
Wakimoto, H.2
Fecci, P.E.3
Ning, J.4
Kuroda, T.5
Jeyaretna, D.S.6
-
108
-
-
45849153869
-
Coordination of early protective immunity to viral infection by regulatory T cells
-
doi:10.1126/science.1155209
-
Lund JM, Hsing L, Pham TT, Rudensky AY. Coordination of early protective immunity to viral infection by regulatory T cells. Science (2008) 320:1220-4. doi:10.1126/science.1155209
-
(2008)
Science
, vol.320
, pp. 1220-1224
-
-
Lund, J.M.1
Hsing, L.2
Pham, T.T.3
Rudensky, A.Y.4
-
109
-
-
79959956606
-
Virus-induced tumor inflammation facilitates effective DC cancer immunotherapy in a Treg-dependent manner in mice
-
doi:10.1172/JCI45585
-
Woller N, Knocke S, Mundt B, Gurlevik E, Struver N, Kloos A, et al. Virus-induced tumor inflammation facilitates effective DC cancer immunotherapy in a Treg-dependent manner in mice. J Clin Invest (2011) 121:2570-82. doi:10.1172/JCI45585
-
(2011)
J Clin Invest
, vol.121
, pp. 2570-2582
-
-
Woller, N.1
Knocke, S.2
Mundt, B.3
Gurlevik, E.4
Struver, N.5
Kloos, A.6
-
110
-
-
78650124721
-
Reprogrammed foxp3(+) regulatory T cells provide essential help to support cross-presentation and CD8(+) T cell priming in naive mice
-
doi:10.1016/j.immuni.2010.11.022
-
Sharma MD, Hou DY, Baban B, Koni PA, He Y, Chandler PR, et al. Reprogrammed foxp3(+) regulatory T cells provide essential help to support cross-presentation and CD8(+) T cell priming in naive mice. Immunity (2010) 33:942-54. doi:10.1016/j.immuni.2010.11.022
-
(2010)
Immunity
, vol.33
, pp. 942-954
-
-
Sharma, M.D.1
Hou, D.Y.2
Baban, B.3
Koni, P.A.4
He, Y.5
Chandler, P.R.6
-
111
-
-
78650861433
-
VSV oncolytic virotherapy in the B16 model depends upon intact MyD88 signaling
-
doi:10.1038/mt.2010.225
-
Wongthida P, Diaz RM, Galivo F, Kottke T, Thompson J, Melcher A, et al. VSV oncolytic virotherapy in the B16 model depends upon intact MyD88 signaling. Mol Ther (2011) 19:150-8. doi:10.1038/mt.2010.225
-
(2011)
Mol Ther
, vol.19
, pp. 150-158
-
-
Wongthida, P.1
Diaz, R.M.2
Galivo, F.3
Kottke, T.4
Thompson, J.5
Melcher, A.6
-
112
-
-
84891825541
-
Immunogenic HSV-mediated oncolysis shapes the antitumor immune response and contributes to therapeutic efficacy
-
doi:10.1038/mt.2013.238
-
Workenhe ST, Simmons G, Pol JG, Lichty BD, Halford WP, Mossman KL. Immunogenic HSV-mediated oncolysis shapes the antitumor immune response and contributes to therapeutic efficacy. Mol Ther (2014) 22:123-31. doi:10.1038/mt.2013.238
-
(2014)
Mol Ther
, vol.22
, pp. 123-131
-
-
Workenhe, S.T.1
Simmons, G.2
Pol, J.G.3
Lichty, B.D.4
Halford, W.P.5
Mossman, K.L.6
-
113
-
-
51349123892
-
Cancer immunotherapy by dendritic cells
-
doi:10.1016/j.immuni.2008.08.004
-
Melief CJ. Cancer immunotherapy by dendritic cells. Immunity (2008) 29:372-83. doi:10.1016/j.immuni.2008.08.004
-
(2008)
Immunity
, vol.29
, pp. 372-383
-
-
Melief, C.J.1
-
114
-
-
0037295403
-
ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties
-
doi:10.1038/sj.gt.3301885
-
Liu BL, Robinson M, Han ZQ, Branston RH, English C, Reay P, et al. ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties. Gene Ther (2003) 10:292-303. doi:10.1038/sj.gt.3301885
-
(2003)
Gene Ther
, vol.10
, pp. 292-303
-
-
Liu, B.L.1
Robinson, M.2
Han, Z.Q.3
Branston, R.H.4
English, C.5
Reay, P.6
-
115
-
-
33845336115
-
A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor
-
doi:10.1158/1078-0432.CCR-06-0759
-
Hu JC, Coffin RS, Davis CJ, Graham NJ, Groves N, Guest PJ, et al. A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor. Clin Cancer Res (2006) 12:6737-47. doi:10.1158/1078-0432.CCR-06-0759
-
(2006)
Clin Cancer Res
, vol.12
, pp. 6737-6747
-
-
Hu, J.C.1
Coffin, R.S.2
Davis, C.J.3
Graham, N.J.4
Groves, N.5
Guest, P.J.6
-
116
-
-
20144382769
-
Assessment of a combined, adenovirus-mediated oncolytic and immunostimulatory tumor therapy
-
doi:10.1158/0008-5472.CAN-04-3527
-
Bernt KM, Ni S, Tieu AT, Lieber A. Assessment of a combined, adenovirus-mediated oncolytic and immunostimulatory tumor therapy. Cancer Res (2005) 65:4343-52. doi:10.1158/0008-5472.CAN-04-3527
-
(2005)
Cancer Res
, vol.65
, pp. 4343-4352
-
-
Bernt, K.M.1
Ni, S.2
Tieu, A.T.3
Lieber, A.4
-
117
-
-
60549100362
-
Antitumoral immune response by recruitment and expansion of dendritic cells in tumors infected with telomerase-dependent oncolytic viruses
-
doi:10.1158/0008-5472.CAN-08-1160
-
Edukulla R, Woller N, Mundt B, Knocke S, Gurlevik E, Saborowski M, et al. Antitumoral immune response by recruitment and expansion of dendritic cells in tumors infected with telomerase-dependent oncolytic viruses. Cancer Res (2009) 69:1448-58. doi:10.1158/0008-5472.CAN-08-1160
-
(2009)
Cancer Res
, vol.69
, pp. 1448-1458
-
-
Edukulla, R.1
Woller, N.2
Mundt, B.3
Knocke, S.4
Gurlevik, E.5
Saborowski, M.6
-
118
-
-
79953327283
-
Chemokine expression from oncolytic vaccinia virus enhances vaccine therapies of cancer
-
doi:10.1038/mt.2010.312
-
Li J, O'Malley M, Urban J, Sampath P, Guo ZS, Kalinski P, et al. Chemokine expression from oncolytic vaccinia virus enhances vaccine therapies of cancer. Mol Ther (2011) 19:650-7. doi:10.1038/mt.2010.312
-
(2011)
Mol Ther
, vol.19
, pp. 650-657
-
-
Li, J.1
O'Malley, M.2
Urban, J.3
Sampath, P.4
Guo, Z.S.5
Kalinski, P.6
-
119
-
-
70349864985
-
Vesicular stomatitis virus as a novel cancer vaccine vector to prime antitumor immunity amenable to rapid boosting with adenovirus
-
doi:10.1038/mt.2009.154
-
Bridle BW, Boudreau JE, Lichty BD, Brunelliere J, Stephenson K, Koshy S, et al. Vesicular stomatitis virus as a novel cancer vaccine vector to prime antitumor immunity amenable to rapid boosting with adenovirus. Mol Ther (2009) 17:1814-21. doi:10.1038/mt.2009.154
-
(2009)
Mol Ther
, vol.17
, pp. 1814-1821
-
-
Bridle, B.W.1
Boudreau, J.E.2
Lichty, B.D.3
Brunelliere, J.4
Stephenson, K.5
Koshy, S.6
-
120
-
-
77955176474
-
Potentiating cancer immunotherapy using an oncolytic virus
-
doi:10.1038/mt.2010.98
-
Bridle BW, Stephenson KB, Boudreau JE, Koshy S, Kazdhan N, Pullenayegum E, et al. Potentiating cancer immunotherapy using an oncolytic virus. Mol Ther (2010) 18:1430-9. doi:10.1038/mt.2010.98
-
(2010)
Mol Ther
, vol.18
, pp. 1430-1439
-
-
Bridle, B.W.1
Stephenson, K.B.2
Boudreau, J.E.3
Koshy, S.4
Kazdhan, N.5
Pullenayegum, E.6
-
121
-
-
84885717771
-
Oncolytic vesicular stomatitis virus quantitatively and qualitatively improves primary CD8 T-cell responses to anticancer vaccines.
-
doi:10.4161/onci.26013
-
Bridle BW, Clouthier D, Zhang L, Pol J, Chen L, Lichty BD, et al. Oncolytic vesicular stomatitis virus quantitatively and qualitatively improves primary CD8 T-cell responses to anticancer vaccines. Oncoimmunology (2013) 2:e26013. doi:10.4161/onci.26013
-
(2013)
Oncoimmunology
, vol.2
-
-
Bridle, B.W.1
Clouthier, D.2
Zhang, L.3
Pol, J.4
Chen, L.5
Lichty, B.D.6
-
122
-
-
84898010085
-
Microsphere priming facilitates induction of potent therapeutic T-cell immune responses against autochthonous liver cancers
-
doi:10.1002/eji.201343794
-
Brinkhoff B, Ostroumov D, Heemcke J, Woller N, Gurlevik E, Manns MP, et al. Microsphere priming facilitates induction of potent therapeutic T-cell immune responses against autochthonous liver cancers. Eur J Immunol (2014) 44:1213-24. doi:10.1002/eji.201343794
-
(2014)
Eur J Immunol
, vol.44
, pp. 1213-1224
-
-
Brinkhoff, B.1
Ostroumov, D.2
Heemcke, J.3
Woller, N.4
Gurlevik, E.5
Manns, M.P.6
-
123
-
-
79960125220
-
Broad antigenic coverage induced by vaccination with virus-based cDNA libraries cures established tumors
-
doi:10.1038/nm.2390
-
Kottke T, Errington F, Pulido J, Galivo F, Thompson J, Wongthida P, et al. Broad antigenic coverage induced by vaccination with virus-based cDNA libraries cures established tumors. Nat Med (2011) 17:854-9. doi:10.1038/nm.2390
-
(2011)
Nat Med
, vol.17
, pp. 854-859
-
-
Kottke, T.1
Errington, F.2
Pulido, J.3
Galivo, F.4
Thompson, J.5
Wongthida, P.6
-
124
-
-
84859646663
-
Using virally expressed melanoma cDNA libraries to identify tumor-associated antigens that cure melanoma
-
doi:10.1038/nbt.2157
-
Pulido J, Kottke T, Thompson J, Galivo F, Wongthida P, Diaz RM, et al. Using virally expressed melanoma cDNA libraries to identify tumor-associated antigens that cure melanoma. Nat Biotechnol (2012) 30:337-43. doi:10.1038/nbt.2157
-
(2012)
Nat Biotechnol
, vol.30
, pp. 337-343
-
-
Pulido, J.1
Kottke, T.2
Thompson, J.3
Galivo, F.4
Wongthida, P.5
Diaz, R.M.6
-
125
-
-
84880721353
-
Dendritic-cell-based therapeutic cancer vaccines
-
doi:10.1016/j.immuni.2013.07.004
-
Palucka K, Banchereau J. Dendritic-cell-based therapeutic cancer vaccines. Immunity (2013) 39:38-48. doi:10.1016/j.immuni.2013.07.004
-
(2013)
Immunity
, vol.39
, pp. 38-48
-
-
Palucka, K.1
Banchereau, J.2
-
126
-
-
84859128199
-
Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape.
-
127ra37, doi:10.1126/scitranslmed.3003689
-
Taube JM, Anders RA, Young GD, Xu H, Sharma R, McMiller TL, et al. Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med (2012) 4:127ra37. doi:10.1126/scitranslmed.3003689
-
(2012)
Sci Transl Med
, vol.4
-
-
Taube, J.M.1
Anders, R.A.2
Young, G.D.3
Xu, H.4
Sharma, R.5
McMiller, T.L.6
-
127
-
-
27644534576
-
The response of autologous T cells to a human melanoma is dominated by mutated neoantigens
-
doi:10.1073/pnas.0500090102
-
Lennerz V, Fatho M, Gentilini C, Frye RA, Lifke A, Ferel D, et al. The response of autologous T cells to a human melanoma is dominated by mutated neoantigens. Proc Natl Acad Sci U S A (2005) 102:16013-8. doi:10.1073/pnas.0500090102
-
(2005)
Proc Natl Acad Sci U S A
, vol.102
, pp. 16013-16018
-
-
Lennerz, V.1
Fatho, M.2
Gentilini, C.3
Frye, R.A.4
Lifke, A.5
Ferel, D.6
-
128
-
-
0023818008
-
Individually distinct transplantation antigens of chemically induced mouse tumors
-
doi:10.1016/0167-5699(88)91269-8
-
Srivastava PK, Old LJ. Individually distinct transplantation antigens of chemically induced mouse tumors. Immunol Today (1988) 9:78-83. doi:10.1016/0167-5699(88)91269-8
-
(1988)
Immunol Today
, vol.9
, pp. 78-83
-
-
Srivastava, P.K.1
Old, L.J.2
-
129
-
-
84862776855
-
Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting
-
doi:10.1038/nature10755
-
Matsushita H, Vesely MD, Koboldt DC, Rickert CG, Uppaluri R, Magrini VJ, et al. Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. Nature (2012) 482:400-4. doi:10.1038/nature10755
-
(2012)
Nature
, vol.482
, pp. 400-404
-
-
Matsushita, H.1
Vesely, M.D.2
Koboldt, D.C.3
Rickert, C.G.4
Uppaluri, R.5
Magrini, V.J.6
-
130
-
-
84875490185
-
Cancer genome landscapes
-
doi:10.1126/science.1235122
-
Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA Jr., Kinzler KW. Cancer genome landscapes. Science (2013) 339:1546-58. doi:10.1126/science.1235122
-
(2013)
Science
, vol.339
, pp. 1546-1558
-
-
Vogelstein, B.1
Papadopoulos, N.2
Velculescu, V.E.3
Zhou, S.4
Diaz Jr., L.A.5
Kinzler, K.W.6
-
131
-
-
84872876150
-
The cancer antigenome
-
doi:10.1038/emboj.2012.333
-
Heemskerk B, Kvistborg P, Schumacher TN. The cancer antigenome. EMBO J (2013) 32:194-203. doi:10.1038/emboj.2012.333
-
(2013)
EMBO J
, vol.32
, pp. 194-203
-
-
Heemskerk, B.1
Kvistborg, P.2
Schumacher, T.N.3
-
132
-
-
84857725402
-
Exploiting the mutanome for tumor vaccination
-
doi:10.1158/0008-5472.CAN-11-3722
-
Castle JC, Kreiter S, Diekmann J, Lower M, van de Roemer N, de GJ, et al. Exploiting the mutanome for tumor vaccination. Cancer Res (2012) 72:1081-91. doi:10.1158/0008-5472.CAN-11-3722
-
(2012)
Cancer Res
, vol.72
, pp. 1081-1091
-
-
Castle, J.C.1
Kreiter, S.2
Diekmann, J.3
Lower, M.4
van de Roemer, N.5
de, G.J.6
-
133
-
-
77954801079
-
Improved survival with ipilimumab in patients with metastatic melanoma
-
doi:10.1056/NEJMoa1003466
-
Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med (2010) 363:711-23. doi:10.1056/NEJMoa1003466
-
(2010)
N Engl J Med
, vol.363
, pp. 711-723
-
-
Hodi, F.S.1
O'Day, S.J.2
McDermott, D.F.3
Weber, R.W.4
Sosman, J.A.5
Haanen, J.B.6
-
134
-
-
84880511594
-
Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma
-
doi:10.1111/nyas.12180
-
Wolchok JD, Hodi FS, Weber JS, Allison JP, Urba WJ, Robert C, et al. Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma. Ann N Y Acad Sci (2013) 1291:1-13. doi:10.1111/nyas.12180
-
(2013)
Ann N Y Acad Sci
, vol.1291
, pp. 1-13
-
-
Wolchok, J.D.1
Hodi, F.S.2
Weber, J.S.3
Allison, J.P.4
Urba, W.J.5
Robert, C.6
-
135
-
-
84872841412
-
Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma.
-
doi:10.1200/JCO.2012.47.7521
-
van RN, van Buuren MM, Philips D, Velds A, Toebes M, Heemskerk B, et al. Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma. J Clin Oncol (2013) 31:e439-42. doi:10.1200/JCO.2012.47.7521
-
(2013)
J Clin Oncol
, vol.31
-
-
van, R.N.1
van Buuren, M.M.2
Philips, D.3
Velds, A.4
Toebes, M.5
Heemskerk, B.6
-
136
-
-
57649123650
-
Recombinant vesicular stomatitis virus targeted to Her2/neu combined with anti-CTLA4 antibody eliminates implanted mammary tumors
-
doi:10.1038/cgt.2008.55
-
Gao Y, Whitaker-Dowling P, Griffin JA, Barmada MA, Bergman I. Recombinant vesicular stomatitis virus targeted to Her2/neu combined with anti-CTLA4 antibody eliminates implanted mammary tumors. Cancer Gene Ther (2009) 16:44-52. doi:10.1038/cgt.2008.55
-
(2009)
Cancer Gene Ther
, vol.16
, pp. 44-52
-
-
Gao, Y.1
Whitaker-Dowling, P.2
Griffin, J.A.3
Barmada, M.A.4
Bergman, I.5
-
137
-
-
84867397020
-
Targeted cancer immunotherapy with oncolytic adenovirus coding for a fully human monoclonal antibody specific for CTLA-4
-
doi:10.1038/gt.2011.176
-
Dias JD, Hemminki O, Diaconu I, Hirvinen M, Bonetti A, Guse K, et al. Targeted cancer immunotherapy with oncolytic adenovirus coding for a fully human monoclonal antibody specific for CTLA-4. Gene Ther (2012) 19:988-98. doi:10.1038/gt.2011.176
-
(2012)
Gene Ther
, vol.19
, pp. 988-998
-
-
Dias, J.D.1
Hemminki, O.2
Diaconu, I.3
Hirvinen, M.4
Bonetti, A.5
Guse, K.6
-
138
-
-
84897476768
-
Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy.
-
226ra32, doi:10.1126/scitranslmed.3008095
-
Zamarin D, Holmgaard RB, Subudhi SK, Park JS, Mansour M, Palese P, et al. Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy. Sci Transl Med (2014) 6:226ra32. doi:10.1126/scitranslmed.3008095
-
(2014)
Sci Transl Med
, vol.6
-
-
Zamarin, D.1
Holmgaard, R.B.2
Subudhi, S.K.3
Park, J.S.4
Mansour, M.5
Palese, P.6
-
139
-
-
70350536582
-
Host lymphodepletion enhances the therapeutic activity of an oncolytic vaccinia virus expressing 4-1BB ligand
-
doi:10.1158/0008-5472.CAN-09-2522
-
Kim HS, Kim-Schulze S, Kim DW, Kaufman HL. Host lymphodepletion enhances the therapeutic activity of an oncolytic vaccinia virus expressing 4-1BB ligand. Cancer Res (2009) 69:8516-25. doi:10.1158/0008-5472.CAN-09-2522
-
(2009)
Cancer Res
, vol.69
, pp. 8516-8525
-
-
Kim, H.S.1
Kim-Schulze, S.2
Kim, D.W.3
Kaufman, H.L.4
-
140
-
-
84858762241
-
Oncolytic virus and anti-4-1BB combination therapy elicits strong antitumor immunity against established cancer
-
doi:10.1158/0008-5472.CAN-11-2788
-
John LB, Howland LJ, Flynn JK, West AC, Devaud C, Duong CP, et al. Oncolytic virus and anti-4-1BB combination therapy elicits strong antitumor immunity against established cancer. Cancer Res (2012) 72:1651-60. doi:10.1158/0008-5472.CAN-11-2788
-
(2012)
Cancer Res
, vol.72
, pp. 1651-1660
-
-
John, L.B.1
Howland, L.J.2
Flynn, J.K.3
West, A.C.4
Devaud, C.5
Duong, C.P.6
-
141
-
-
84862859820
-
Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer
-
doi:10.1056/NEJMoa1200690
-
Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer. N Engl J Med (2012) 366:2443-54. doi:10.1056/NEJMoa1200690
-
(2012)
N Engl J Med
, vol.366
, pp. 2443-2454
-
-
Topalian, S.L.1
Hodi, F.S.2
Brahmer, J.R.3
Gettinger, S.N.4
Smith, D.C.5
McDermott, D.F.6
-
142
-
-
84895907145
-
Oncolytic virotherapy and immunogenic cancer cell death: sharpening the sword for improved cancer treatment strategies
-
doi:10.1038/mt.2013.220
-
Workenhe ST, Mossman KL. Oncolytic virotherapy and immunogenic cancer cell death: sharpening the sword for improved cancer treatment strategies. Mol Ther (2014) 22:251-6. doi:10.1038/mt.2013.220
-
(2014)
Mol Ther
, vol.22
, pp. 251-256
-
-
Workenhe, S.T.1
Mossman, K.L.2
-
143
-
-
84901044424
-
Oncolytic immunotherapy: dying the right way is a key to eliciting potent antitumor immunity.
-
doi:10.3389/fonc.2014.00074
-
Guo ZS, Liu Z, Bartlett DL. Oncolytic immunotherapy: dying the right way is a key to eliciting potent antitumor immunity. Front Oncol (2014) 4:74. doi:10.3389/fonc.2014.00074
-
(2014)
Front Oncol
, vol.4
, pp. 74
-
-
Guo, Z.S.1
Liu, Z.2
Bartlett, D.L.3
-
144
-
-
84879777241
-
Nivolumab plus ipilimumab in advanced melanoma
-
doi:10.1056/NEJMoa1302369
-
Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med (2013) 369:122-33. doi:10.1056/NEJMoa1302369
-
(2013)
N Engl J Med
, vol.369
, pp. 122-133
-
-
Wolchok, J.D.1
Kluger, H.2
Callahan, M.K.3
Postow, M.A.4
Rizvi, N.A.5
Lesokhin, A.M.6
|